SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Biogen’s Diranersen Slows Alzheimer’s Clinical Decline 38% in Phase 2 Study

Diranersen slowed Alzheimer’s clinical decline by 38% at two years in a Phase 2 study.

BIIB

Related stories